Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24173421 | 0.91 | ALDH1A1 (0.36) | P2RX7MAPTLMNASMN1; SMN2PKM | |
| SCHEMBL22845346 | 0.91 | MGLL (0.36) | MGLLP2RX7MAPTLMNASMN1; SMN2 | |
| SCHEMBL26842658 | 0.90 | MAPT (0.35) | P2RX7MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL22845339 | 0.89 | P2RX7 (0.35) | P2RX7MAPTLMNAPKMALDH1A1 | |
| SCHEMBL24483838 | 0.89 | HDAC1 (0.35) | P2RX7MAPTLMNAALDH1A1TP53 | |
| SCHEMBL22845425 | 0.89 | MTHFD2 (0.33) | P2RX7MAPTLMNASMN1; SMN2PKM | |
| SCHEMBL26842714 | 0.89 | PDE2A (0.34) | P2RX7MAPTLMNASMN1; SMN2TP53 | |
| SCHEMBL24469797 | 0.88 | ALDH1A1 (0.33) | P2RX7MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL22845445 | 0.87 | MAPT (0.35) | P2RX7MAPTALDH1A1TP53 | |
| SCHEMBL26842700 | 0.87 | MTHFD2 (0.31) | P2RX7MTHFD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MGLL 1416/4885P2RX7 2406/4885CFTR 6/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MGLL 1416/4885P2RX7 2406/4885CFTR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.